Tempest Therapeutics adds board member, new CFO, and related-party R&D deal with Factor BioscienceSep 28PeopleTempest Therapeutics
Tempest secures option to license Senlang's CD7 lentiviral in vivo CAR-T platformSep 17PartnershipTempest Therapeutics
Tempest Therapeutics registers 8.9 million shares for Lincoln Park equity lineAug 21FinancingTempest Therapeutics
Tempest Therapeutics signs up to $50 million stock purchase deal with Lincoln Park CapitalAug 13PartnershipTempest Therapeutics
Tempest reports Q2 2026 results, in vivo CAR-T collaboration with Senlang BiotechnologyAug 13Quarterly updateTempest Therapeutics
Tempest partners with Senlang on CD7-targeted in vivo CAR-T for autoimmune diseaseJul 22PartnershipTempest Therapeutics
Sign in